MeTA Ghana Overview. MeTA Global Meeting 1-4 December, 2014 Chavannes de Bogis, Switzerland

Transcriptie

1 Ghana Overview Global Meeting 1-4 December, 2014 Chavannes de Bogis, Switzerland

2 in Ghana Context Registered as a public not for profit organisation, and chaired by public and private sectors Multistakeholders in pharmaceutical sector engaged on GC Larger stakeholder body engaged via open fora etc. Structure IMS GC: Highest decision body-a broad 19 member GC with associated institutional representation with dual CSO representation A secretariat (Coordinator and Admin Assistant reporting to the Council and directly to Chair, Deputy Chair)

3 in Ghana Operations Scope of work is largely driven by approved Ghana workplan Administrative issues-under an admin sub-group with admin sub-group chair Technical issues-under technical sub group with technical subgroup chair Advocacy issues-under advocacy sub group with advocacy subgroup chair

4 Key activities Policy Contribution to National Drug Policy review 2014 Assessment of transparency-training: Methodology of transparency assessments Multi-stakeholder engagements stakeholder fora [March and October 2014] CSO Programme Study: Assessment of knowledge attitudes beliefs and practices

5 Key dissemination activities forum Disseminated existing information on Quality of pharmaceuticals; on Good governance of pharmaceuticals; the impact of medicines prices on national health insurance Web-based dissemination of actions alongside implementation of workplan Presentation at NHIA stakeholder fora Dissemination of CSO KABP report postponed till after global meeting

6 Media update of the issues 16/09/2008 6

7 Media update of the issues 16/09/2008 7

8 Some pictures 1 st forum

9 2 nd forum

10 Main policy recommendations Creation of an enabling environment for transparent processes and procedures within the pharmaceutical sector A central Management Information Systems (MIS) to enhance access to information on health technologies including pharmaceuticals Adequate sharing of information to strengthen the capacity of consumers to demand accountability from providers with commensurate responsibility from consumers The establishment of a multi-stakeholder platform to share information on the pharmaceutical sector

11 Achievements Immediate outputs: Policy recommendations on transparency Country capacity built on transparency assessments including CSO as one of the organizations promoting transparency in health Knowledge attitudes beliefs and practices of CSOs assessed on access to medicines and transparency Stakeholders engaged on quality of medicines; governance; pricing and health insurance Communiqué on medicines prices to government

12 Challenges and Opportunities Challenges Timeliness of release of funds Opportunities Government committed to transparency Legislation, Upcoming bill on right to information Committed governing council Committed multi-sectorial leadership Committed secretariat CSO collaboration: over 400 CSOs across Ghana

13 Current and planned activities National assessment of transparency and follow through actions Policy actions and evidence on medicines pricing Baseline assessment and interventions to strengthen Drugs and Therapeutic Committees Continued engagement of stakeholders and high-level policy makers and follow through actions e.g. post forum actions on medicines quality and medicines pricing Availability and Pricing survey DTC interventions and monitoring CSO capacity building and advocacy actions

14 Current and planned activities Emergent issues from stakeholder for a requiring programme level actions Informal medicines market Aspects of the outcomes on RUM/DTC are clear programme level actions Transparency assessment leads to governance and framework and implementation requiring follow through actions

15

16 Thank you